Table 5.
Comparison of serum free light chain (FLC) concentration by IMMAGE at starting sample dilution (1 in 10) and higher offline-sample dilutions.
| Patient ID: | FLC concentration (mg/L) after multiplication at final sample dilution |
|||||
|---|---|---|---|---|---|---|
| 1 in 10 a | 1 in 20 | 1 in 30 | 1 in 50 | (Other dilution) | 1 in 110 | |
| κFLC:b | ||||||
| LCMM (nonlinear) | 47 | 90 | 120 | 141 | 153 (1 in 80) | 154 |
| AL (nonlinear) | 63 | 106 | 113 | 116 | - | - |
| AL and LCMM | 143 | - | 245 | 237 | - | - |
| LCMM | 88 | - | 179 | 184 | - | - |
| IIMM | 127 | 236 | 272 | 289 | 291 (1 in 90) | - |
| NSMM | 108 | - | 297 | 303 | - | - |
| λFLC:c | ||||||
| LCMM | 208 | 420 | - | 411 | - | 391 |
| IIMM | 110 | 138 | 147 | 147 | - | - |
| IIMM | 212 | - | 327 | - | 277 (1 in 60) | - |
| LCMM | 190 | - | 271 | - | 254 (1 in 60) | - |
| IIMM | 214 | - | 318 | 286 | - | - |
a
IMMAGE starting sample dilution was 1 in 10;
b
κFLC upper measuring limit: approx. 180 mg/L:
c
λFLC upper measuring limit: approx. 240 mg/L.
AL, amyloidosis; IIMM, intact immunoglobulin myeloma; LCMM, light chain myeloma; NSMM, non-secretory myeloma.